Erythromycin brands in australia

Buy zoloft brand online


Zoloft Bestellen Rezeptfrei
3-5 stars based on 888 reviews

This medicine is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, panic disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder (social phobia), and a severe form of premenstrual syndrome called premenstrual dysphoric disorder (PMDD).

Zoloft online buy at: http://store.opentecare.com.zoloft/ Phenelzol (for insomnia). Online (from 9am AEST, Australia time), or call 1.888.345.4555 Somatropin. Pharmacy (from 1pm AEST, Australia time), 24hrs free if prescription is in-store: 1.800.261.4357, or 1.800.844.0248 on mobile: 99999 Tricyclic antidepressants such as Zoloft and Effexor available over the counter. Online at: http://onlinepills.ca The above information is provided as a general guide only and does not replace the advice of your doctor or pharmacist. The information is not intended to replace your actual medical decision-making. For general advice please seek the of a qualified health care practitioner. The former owner of the "Homes Misery" blog on internet accused of child porn charges was arrested by the FBI today in Los Angeles. "I am deeply disgusted by the FBI's decision to release a video of my friend and former landlord Jeffrey Epstein. It is nothing more than the FBI's attempt to save its reputation. The public should never have had to see this. This video is nothing short of a hate crime – and yet, here Mr. Epstein is in handcuffs and out of jail," said Robert Durst in a written statement. The arrest was made at his residence in Calabasas. It has been described as "random, unregistered and unannounced, in, his door was opened and personal belongings Zoloft 90 Pills 100mg $99 - $1.1 Per pill were strewn all over the floor of his home." "There's literally a dozen agents in full Proscar ohne rezept bestellen tactical gear surrounding my door, yelling to me come out, and all I can remember asking them is why. So many questions for which I remain stumped. But when the handcuffs were put on me, I was in handcuffs before even had an opportunity drug store west seattle to ask what they mean. I think that proves how much they want to sweep this under the rug before it hits news cycle," said Durst on the arrests. In a statement to the media "I am pleased to announce that I am in the custody of United States Marshals and the FBI, under authority of US Marshals Service, at my request," the author told ABC He did not indicate whether has retained an attorney. The blog was taken down in March this year. It was accused by a former employee of having "cult personality" on the internet. He accused Durst of using it as an alibi for child porn crimes. The FBI said it took precaution of shutting down the website because it did not want the "misleading material" posted online. "From the beginning, my only intentions have been to assist the D.A. for any and all action in cases of child sexual abuse that Jeffrey Epstein might be a target or suspect in. Unfortunately, that is now in doubt, and I see no way to salvage what has been lost," said Durst in a written statement. "On behalf of my family and me, I am grateful that our time together cannot be defined by this nightmare. "What is certain that this nightmare only began, and it will end. I believe this due to the actions of those who have put their personal agendas ahead of innocent men who may very well have done nothing wrong." "I been with my husband and children since they were small toddlers. My husband is a nurse so he has been with me over the last several decades and I am grateful for that experience. I was just told last week that he is getting married and so I am a part of the ring and engagement process while I find a new job. My husband is very old-fashioned and still loves my children like they are his own. The wedding was scheduled for June, about 4 weeks from now. I was very excited at first. It was a surprise proposal. As if we were preparing for the wedding then getting married was like our new house on the market...I thought, wow! Who knew? We are finally having a wedding we want and when I decided it might take awhile I was happy about that. also very eager to start a career when I started my job. kids were always on the road at various jobs which was great so I don't have a ton of homework until we are both in our 20's. My husband and I enjoy having a garden or kids and it is a good way to get away once in a while. We have three dogs...they make me smile, they keep happy, and out the bugs. I will miss seeing them, but it will just be a special moment for the family." "We decided to get married in"

  1. Biberach an der Riß
  2. Zoloft Kaltenkirchen
  3. Overath
  4. Erding
  5. Emmerich am Rhein


buy generic zoloft canada
zoloft rezeptfrei bestellen
buy zoloft generic online
buy zoloft brand online
buy generic zoloft
zoloft rezeptfrei kaufen
zoloft buy online canada
buy generic zoloft online

Zoloft 60 Pills 100mg $69 - $1.15 Per pill
Zoloft 60 Pills 100mg $69 - $1.15 Per pill
Zoloft 60 Pills 50mg $60 - $1 Per pill
Zoloft 90 Pills 100mg $99 - $1.1 Per pill
Zoloft 90 Pills 100mg $99 - $1.1 Per pill
Zoloft 90 Pills 50mg $95 - $1.06 Per pill



Cheap cialis without prescription Augmentin 875 mg price Xenical where to buy


Zoloft buy online uk |http://amzn.to/1j4QgFn[/url] [url=http://openprazi.org/free-review][b]OpenPrey - review[/b] http://www.openprayers.org/free-review.htm [url=http://www.openvoxer.org/free-review][b]OpenVoxer - review[/b] http://www.openvoxer.org/free-review.htm [url=http://www.opensourcepets.com/open-voxer-review][b]OpenVoxer - review[/b] http://www.opensourcepets.com/open-voxer-review.htm [url=http://t3tr1.com/forum/index.php][b]T3 Tr1 Presents[/b]/"New Review" http://t3tr1.cx/forum/index.php [url=http://www.rpgdesignmagazine.com/?c=1]RPG Design[/url] [url=http://rpgdesignmagazine.com/games.asp?index=1 ]RPG Design[/url] [url=http://rpgdesignmagazine.com/features.asp?pub=3]RPG Design[/url] [url=http://www.thegamesjournal.net/index.php?c=1]The Games Journal[/url] [url=http://www.rpgworkshop.com/index.php?c=1]Rpg Workshop[/url] [url=http://rpgmodder.com/reviews.php]RPG Modders | [url=http://rpgmodder.com/rgs.php?page=show.asp&cat=4&id=9]Reviews[/url][/b] by Steve Mosko http://www.rpgmodder.com [/url] [url=http://www.rpgworkshop.com/index.php?c=1]Rpg Workshop[/url] [url=http://www.rpgmodder.com/reviews.php?c2=1]Reviews by David O'Harahttp://www.rpgworkshop.com [/url] [url=http://www.rpgmodder.com/reviews.php?c4=1]David O'Hara's Final Zoloft 60 Pills 50mg $60 - $1 Per pill Review[/url] [url=http://www.rpgworkshop.com/index.php?c=1]David O'Hara's Final Review[/url] [url=http://rpgmodder.com/reviews.php?c=1]David drug store online usa O'Hara's Final Review[/url] [b]Games, RPG & Horror Games - Review[/b] http://www.reviewworld.org/Games/Sci-Fi/Monster-Quest-Review/104095 http://www.reviewworld.org/Sci-Fi/Lords-of-the-Shadows Review/104095 http://www.reviewworld.org/Sci-Fi/Lords-of-the-Shadows-Review/104096

  • Zoloft in N.m.
  • Zoloft in San buenaventura (ventura)
  • Zoloft in Coquitlam
  • Zoloft in Alberni-clayoquot
  • Zoloft in Hartford


Grants PassCommerce CityZoloft Greenfield
BrooklynMerchantvilleZoloft Donaldsonville
OakdaleGrove HillSalinas


< Amoxicillin clavulanate purchase :: Tadalafil for sale cheap >

Canada prescription drug prices

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Mahesh Shah (MBA) as Executive Chairman to lead the business as it expands into the TB diagnostics space.
Mahesh Shah was the founder and CEO of the retail pharmacy business Nucare PLC, a company with operations in the UK as well as overseas. Under his stewardship the business grew both organically and through joint ventures and acquisitions, and he led a successful trade sale in 2007, realising an enterprise value of approximately £70 million.

Mr Shah has professional qualifications in pharmacy, accounting, finance and business, and has extensive practical expertise in international business. He has held board positions with a number of start-up companies, playing a significant role in strategy and commercial agreements.

He has been involved with ProteinLogic for over 5 years, in executive and non-executive roles, and in this time, amongst other achievements, he has successfully raised over £5m in funding and forged productive collaborations with academics, research scientists, clinicians and third party suppliers and contractors.

Mr Shah’s commercial expertise and professional knowledge of the healthcare sector will be a particular asset when it comes to developing ProteinLogic’s commercial offering. On agreeing his appointment, Mr Shah commented: “Having been a part of the PL family for some years, I am enthusiastic about the company’s potential and I look forward to augmenting its growth and steering it through any future challenges. I am delighted to have a talented and committed team around me as we pursue our commercial and technical ambitions.”

Cialis over the counter alternatives

A European Consortium of leading academic and clinical partners, including ProteinLogic, a UK based biomarker discovery company, have been awarded a grant by the European Union Horizon 2020 SME program to help harness the diagnostic power of genome sequencing in day-to-day clinical practice.

ProteinLogic are pleased to announce they have been awarded €415,000 by the European Commission, for the development of a new cancer diagnostic test, comprising both genomic and proteomic biomarkers. The funding was awarded as a result of a successful €2.95 million grant application in partnership with five other European Clinical and Academic Collaborators.
The ability to sequence the complete genome holds great promise in the prevention and treatment of cancer. However, there are significant challenges in translating genome sequence information into clinical cancer practice. The goal of this project is to integrate genomic data with proteomic data to develop diagnostic tools for better risk assessment and early diagnosis of cancers. The combination of genomic data and proteomic data may also allow the prediction of response to drugs, disease burden, and likelihood of recurrence.

The three year €2.95 million project will expand and integrate ProteinLogic’s unique panel of biomarker proteins with genetic and epigenetic biomarkers selected from the very large public databases as well as biomarkers identified from clinical samples analysed under the program. The project also addresses the full chain of computational and statistical tools that are needed for clinically relevant diagnosis and intervention, including discovery in large cohorts, validation of putative causal sites in model systems and development of targeted cancer-risk panels. The project will deal with critical aspects of how data are collected, stored, organized, integrated, analysed and exploited in cancer genetic clinics. The project aims to provide a concerted, cross-disciplinary framework for better understanding, integration and use of cancer clinical data in the evaluation of the multitude of genetic variants and mutations involved in cancer susceptibility, for the direct benefit of cancer patients. The project will focus on breast cancer, colorectal cancer and stomach cancer.

The consortium brings together complementary expertise. It is led by Professor Angel Carracedo who is an international expert in the genetics of Mendelian and complex traits, including pharmacogenomics, as well as in population genetics; and heads the Foundation of Genomic Medicine of Galicia, Spain. Dr Xavier Estivill is the head of the Genomics and Personalized Medicine Unit, University Hospital Quirón Dexeus, Women’s Health Department, Spain. Dexeus is one of the largest private clinics in Europe that is exclusively devoted to women’s health. Dr Aura Carerra is the group leader of the Genotoxic and Stress Unit at the prestigious Curie Institute, France. The European Molecular Biology Laboratory has made many scientific breakthroughs and its London branch, the EMBL-EBI is a hub for bioinformatics research and services, developing and maintaining a large number of scientific databases. Dr Stephan Ossowski heads the Genomic and Epigenomic Variation in Disease group at the Centre for Genomic Regulation in Barcelona, an international biomedical Research Institute of Excellence.

ProteinLogic’s Chairman Mahesh Shah said: “We are delighted that the European Commission is funding this exciting collaboration of European experts in the field of cancer genomics. As the only commercial organisation in the consortium, we hope to contribute both ProteinLogic’s proprietary proteomic know-how as well as lead on any commercial opportunities that might arise from this project.”

ENDS

Further information:
Mahesh Shah, ProteinLogic Ltd, telephone: +44 (0) 203 178 2045 mahesh.shah@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in the blood and other body fluids.

Horizon 2020

euflagHorizon 2020 is the financial instrument of the European Union, implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. Horizon 2020 is the biggest ever EU research and innovation program. Through the SME Instrument, the European Union wants to finance the most innovative small companies with a high growth potential. The program promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.
By coupling research and innovation, Horizon 2020 is helping to drive economic growth with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.
Selected SMEs, showing a strong ambition to develop, grow and internationalise, shall be supported across Horizon 2020 with a dedicated instrument to provide staged and seamless support covering the whole innovation cycle.

For more information please visit http://cordis.europa.eu/programme/rcn/664237_en.html

Dutasteride cost australia

ProteinLogic, a biomarker discovery company, and its collaborator, Biosensia, an in vitro diagnostic company have been awarded a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB).

rapiflex

Almost 9m new cases of TB occur annually and there are over 1.4m deaths every year despite most cases being curable. More than 3m people contracting TB each year go undiagnosed and untreated according to the World Health Organisation. WHO is now calling for accelerated uptake of new tools and strategies for better diagnosis, treatment and prevention of all forms of TB. The ProteinLogic TB test will enable the rapid diagnosis of the active form of TB using a simple blood sample that can be taken and analysed at the point-of-care.

The three year €3.58million project will integrate ProteinLogic’s unique panel of biomarker proteins with Biosensia’s RapiPlex rapid diagnosis platform which can rapidly determine levels of multiple proteins in blood within 15-20 minutes and is suitable for use in a local community healthcare setting. The EU funding, under the dedicated instrument “Clinical research for the validation of biomarkers and/or diagnostic medical devices”, will be used to create a prototype device for rapid, point-of-care human TB diagnostics.

Infectious diseases (e.g. HIV/AIDS, tuberculosis and malaria), are a global concern, accounting for 41% of the 1.5 billion disability adjusted life years worldwide, with 8% of these in Europe.

The program is enhanced by the expertise of several global academic TB Groups who are currently working in the field to help eradicate the disease and who understand, first hand, what is needed for a rapid TB diagnostic. These include Imperial College London, University College London, the University of Cape Town (UCT) in South Africa and the Foundation for Innovative New Diagnostics (FIND). Prof. Ajit Lalvani is Chair of Infectious Diseases, National Institute of Health Research Senior Investigator and Wellcome Senior Clinical Research Fellow at Imperial College London. Dr Marc Lipman is Senior Lecturer & Honorary Consultant Physician in Respiratory & HIV Medicine at the Royal Free Hospital, London and also Deputy Director of UCL-TB Centre. Prof Keertan Dheda is Professor of Respiratory Medicine and Head of the Lung Infection and Immunity Unit at University of Cape Town. FIND is a not-for-profit foundation whose aim is to provide innovative and affordable diagnostic products for all levels of the health care system in developing countries.

ProteinLogic’s Chairman Mahesh Shah said: “We are thrilled that the European Commission is funding this exciting collaboration, especially in light of the very high level of entries. The EU received 580 project proposals involving 785 SMEs and we are particularly pleased to have been selected after evaluation by independent experts. We are looking forward to working with our partners to develop a prototype device and accelerate the development of this innovation for the benefit of patients.”

ENDS

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline.

Horizon 2020

euflagHorizon 2020 is the financial instrument of the European Union, implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness. Horizon 2020 is the biggest ever EU research and innovation program. Through the SME Instrument, the European Union wants to finance the most innovative small companies with a high growth potential. The program promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market.

By coupling research and innovation, Horizon 2020 is helping to drive economic growth with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Selected SMEs, showing a strong ambition to develop, grow and internationalise, shall be supported across Horizon 2020 with a dedicated instrument to provide staged and seamless support covering the whole innovation cycle.

For more information please visit http://cordis.europa.eu/programme/rcn/664237_en.html

Consortium led by ProteinLogic awarded £1.2m grant by the UK’s innovation agency, the Technology Strategy Board, to develop a rapid point-of-care TB test

CAMBRIDGE, UK (2013-11-12) – ProteinLogic, a biomarker discovery and exploitation company, Microtest Diagnostics, an in vitro diagnostic protein multiplexing company, and its collaborators have been awarded a grant by the government-backed Technology Strategy Board – the UK’s national innovation agency – to help support the development of MICROLOGIC™, a rapid point-of-care test for tuberculosis (TB).

Almost 9m new cases of TB occur annually and there are over 1m deaths every year despite most cases being curable. More than 3m people contracting TB each year go undiagnosed and untreated according to the World Health Organisation. WHO is now calling for accelerated uptake of new tools and strategies for better diagnosis, treatment and prevention of all forms of TB. The MICROLOGIC™ test will enable the rapid differentiation of the active and latent forms of TB using a simple blood sample that can be taken and analysed at the point-of-care.

The three year £1.8m project will integrate ProteinLogic’s unique panel of biomarker proteins with Microtest Diagnostic’s CE-marked rapid diagnostic platform which can rapidly determine levels of multiple proteins in blood within a few hours and is suitable for use in a local doctor’s office. The Technology Strategy Board funding will be used to create a prototype device for rapid, point-of-care human TB diagnostics.

The consortium has been enhanced by the expertise of various global academic TB Groups who are currently working in the field to help eradicate the disease and who understand, first hand, what is needed for a rapid TB diagnostic. These include the London School of Hygiene & Tropical Medicine (LSHTM), the University of Sheffield and the University of Cape Town (UCT) in South Africa. Dr Ruth McNerney of LSHTM and Prof Keertan Dehda of UCT are members of the STOP TB Working Group on New Diagnostics and Dr McNerney chairs the subgroup on point-of-care tests. She is also an advisor to the UK All Party Parliamentary Group on TB.

ProteinLogic’s Chairman Dr Paul Rodgers said: “We are thrilled that the Technology Strategy Board is funding this exciting collaboration. We are

looking forward to working with our partners to develop a prototype device and accelerate the application of this innovation for the benefit of patients.”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline including a novel test to stratify patients with chronic hepatitis B infection.

www.proteinlogic.com

Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills, the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

Cheapest cialis at pharmacy

CAMBRIDGE, UK (2013-06-21) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Aron Rachamim as Chief Operating Officer (COO) to provide technical and business leadership in the execution of the company’s R&D and business development strategies.

Aron graduated from the University of Oxford with an MPhys in Physics, following which he obtained an MPhil in Micro- & Nanotechnology Enterprise from the University of Cambridge. He then stayed on at Cambridge to study for a PhD in Engineering working on biosensors. Prior to joining ProteinLogic he founded a university spin-out company and practised as an independent management consultant. His combination of relevant technical and business experience will be a real asset to the Company.

ProteinLogic’s Chairman Dr Rodgers said: “We are delighted to welcome Aron to his new role at ProteinLogic. His appointment will strengthen the Company’s management team and increase our executive capacity. We look forward to working with him as he plays a significant role in the further development of the Company”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first two products in the pipeline are novel diagnostic blood tests for tuberculosis and hepatitis B virus infections. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins found in blood and other body fluids.
www.proteinlogic.com

ProteinLogic wins Med Tech award at NHS Healthcare Innovation Expo 2013

CAMBRIDGE, UK (2013-03-25) – ProteinLogic, the biomarker discovery and exploitation company, was judged to have presented the strongest proposal in the Med Tech category to the Innovators’ Den at the NHS Healthcare Innovation Expo 2013 in London on March 14th.

ProteinLogic’s Chairman Dr Paul Rodgers presented the winning pitch to a panel including leading venture capitalists and senior NHS decision makers in front of a live audience. He outlined the ProteinLogic technology and its progress in implementing a business strategy to commercialise biomarker-based diagnostic tests for a range of diseases including tuberculosis and hepatitis B.

Eighty companies entered the competition and five were selected to present at the Innovators’ Den in each of three categories: Digital Innovations, Med Tech and Service Challenges. The competition was organised by the Technology Strategy Board and Capita.

Dr Rodgers said: “We are delighted with the recognition of ProteinLogic’s innovative technology and its business proposition provided by the distinguished panel of investors and NHS decision makers. We thank the Technology Strategy Board for giving us the opportunity to participate in the Innovators’ Den.”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB and hepatitis B diagnostic tests there are a number of potential follow-on products in the Company’s pipeline.
www.proteinlogic.com

Buy dapoxetine canada

CAMBRIDGE, UK (2013-02-18) – ProteinLogic awarded Technology Strategy Board funding to support its research into a novel diagnostic test for tuberculosis
ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board – the UK’s national innovation agency – to help support the development of a new diagnostic test for tuberculosis (TB).

ProteinLogic has identified a panel of biomarker proteins that has the potential to form the basis of a simple diagnostic blood test to differentiate between patients with active and latent TB infections. The Technology Strategy Board funding, awarded through the Biomedical Catalyst programme, will enable ProteinLogic to carry out clinical feasibility studies to optimise the test, and to provide proof of confidence before committing to an R&D programme to develop the test. The funding will also support market research to identify the optimum route to market, and to develop a commercialisation plan.

Existing TB diagnostic technology is globally acknowledged to be sub-optimal. This project aims to develop a new methodology for the diagnosis of active TB, and for differentiation from the latent form. Accurate, early diagnosis and treatment of TB reduces the prevalence of infective cases and has dramatic potential for disease control. Existing TB diagnostic methodologies are dependent on the isolation of the microorganism from clinical samples; this new diagnostic test utilises the profiling of the unique immunological response to TB infection to confirm the diagnosis.

ProteinLogic’s Chairman Dr Paul Rodgers said: “We are delighted that the Technology Strategy Board is funding this project. Their funding will allow us to continue to optimise our novel TB test and to develop a commercialisation plan. We thank the Technology Strategy Board for its support.”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB diagnostic test there are a number of potential follow-on products in the Company’s pipeline including a novel test to stratify patients with chronic hepatitis B infection.

www.proteinlogic.com

Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills, the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org
The funding was awarded by the Technology Strategy Board through the Biomedical Catalyst programme. The £180 million Biomedical Catalyst is an integrated translational funding programme jointly operated by the Medical Research Council and the Technology Strategy Board providing responsive and effective support for the best life science opportunities arising in the UK.

Standard dose of trazodone for sleep

CAMBRIDGE, UK (2012-09-03) – ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board – the UK’s national innovation agency – to help support the development of a new Diagnostic Test for Hepatitis B.
ProteinLogic has identified a panel of biomarker proteins that has the potential to form the basis of a simple diagnostic blood test to stratify patients with chronic hepatitis B infection. The Technology Strategy Board funding will enable ProteinLogic to undertake market research to establish whether there is a commercially viable market opportunity and to carry out a small clinical study to provide proof of confidence before committing to an R&D programme to develop the test.

A successful diagnostic test would enable personalised treatment of patients suffering from hepatitis B infection, leading to better clinical outcomes and better compliance. The NHS itself would be expected to benefit from significant savings as the expensive treatments would be targeted to patients that are most likely to have a sustainable response.

ProteinLogic’s Chairman Dr Paul Rodgers said: “We are delighted that the Technology Strategy Board is funding this project. Their funding will allow us to collaborate with Professor Graham Foster at Barts Health and Queen Mary University of London where he leads the Liver Unit’s research programme on clinical and scientific aspects of chronic viral hepatitis. We thank the Technology Strategy Board for its support”

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

ProteinLogic’s development pipeline comprises 14 different ImmiPrint® signatures in disease areas including infectious, inflammatory, autoimmune, oncology and metabolic diseases. Following commercial analysis, the Company has identified a significant unmet need for a simple, rapid, and inexpensive blood test that is capable of diagnosing tuberculosis (TB). Early clinical studies indicate that the ImmiPrint® TB signature may be able to discriminate between active and latent forms of TB. The novel hepatitis B diagnostic test is one of a number of potential follow-on products in the Company’s pipeline.

www.proteinlogic.com

Technology Strategy Board

The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

The funding was awarded by the Technology Strategy Board through its SBRI competition for development contracts “Stratified medicine: Determining patient response”. The competition has been developed in collaboration with the partners of the Technology Strategy Board’s Stratified Medicine Innovation Platform to address the key issue identified in the Stratified Medicine Technology Roadmap to incentivise uptake of new stratified medicine approaches within the UK healthcare system.

ProteinLogic appoints Dr. Berwyn Clarke as new Non-Executive Director

CAMBRIDGE, UK (2012-07-31) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Berwyn Clarke as a Non-Executive Director.  Dr Clarke joins the ProteinLogic Board with 25 years’ experience in diagnostics and pharmaceuticals working for start-ups and global businesses such as GlaxoWellcome and Bayer Diagnostics. He is Founder and Chief Scientific Officer of Lab21 Ltd, a rapidly growing healthcare diagnostics business, providing state-of-the-art diagnostic infectious disease products to blood-banks and clinical labs on a worldwide basis; molecular diagnostic products; and molecular diagnostic services in personalised medicine, mainly in oncology. Dr Clarke played a leading role in taking Lab21 from a start-up in 2005 to a significant global player in diagnostic products and services today with service operations in Europe and North America and sales into over 130 countries.

ProteinLogic’s Chairman Dr Paul Rodgers said: “I am delighted that Berwyn has joined the Board where his business and diagnostics industry expertise will help commercialisation of the Company’s ImmiPrint® biomarker technology. The Board believes that Berwyn’s skills, knowledge and expertise will help progress the Company’s development plans to the next stage.”

Dr Clarke said: “I am thrilled to be joining the Company at this exciting stage of its development and I am looking forward to working with the ProteinLogic team.

ENDS

Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146 paul.rodgers@proteinlogic.com

ProteinLogic

ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has

developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

ProteinLogic’s development pipeline comprises 14 different ImmiPrint® signatures in disease areas including infectious, inflammatory, autoimmune, oncology and metabolic diseases. Following commercial analysis, the Company has identified a significant unmet need for a simple, rapid, and inexpensive blood test that is capable of diagnosing tuberculosis (TB). Early clinical studies indicate that the ImmiPrint® TB signature may be able to discriminate between active and latent forms of TB.

www.proteinlogic.com